OncoSec Announces Positive Interim Data From Phase II Study
We are a biotech company developing treatments for advanced-stage skin cancer. Our non-invasive investigational therapies are designed to destroy solid tumors and metastatic cancer and preserve quality of life.
Using DNA IL-12, ImmunoPulse is designed to stimulate the body’s immune system and enable it to recognize, target, and destroy cancerous cells.
NeoPulse can boost the delivery or uptake of the cancer drug bleomycin, enabling a more highly concentrated local delivery with potentially less-debilitating treatment.